The effect was dose-dependent; at 12 weeks of age, diabetes was observed in 80%, 50% and 35% of NOD females treated with 0.8 mg, 0.4 mg or 0.2 mg of anti-GITR, respectively (figure 1A). The gene discussed is TNFRSF18; the disease is diabetes mellitus.